Related Experiment Video
Updated: Aug 24, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: phase II trial
Monika Serke1, Nikolas Schoenfeld, Robert Loddenkemper
1Zentralklinik Emil von Behring, Department Lungenklinik Heckeshorn, Zum Heckeshorn 33, 14109 Berlin, Germany. m.serke@zevb.de
Background:
Open-label, single-centre Phase II trial evaluating the toxicity and antitumour activity of weekly docetaxel in the second-line management of advanced non-small cell lung cancer (NSCLC).
Patients And Methods:
Treatment comprised docetaxel 35 mg/m2 weekly for 6 weeks followed by 2 weeks' rest for a maximum of 3 cycles.
Results:
Thirty-six patients received 220 weekly doses of docetaxel. Toxicity was generally mild: no grade 3-4 haematological toxicity; one grade 4 non-haematological event (bloody diarrhoea in a patient with pre-existing colon diverticulitis). Nausea (11%) and asthenia (8%) constituted the main grade 3 non-haematological toxicities. The objective response rate was 11% (14% minor response, 25% stable disease) and the median duration of survival upon the initiation of docetaxel was 160 days, with a 1-year survival rate of 23%.
Conclusion:
Docetaxel is active and well tolerated in the second-line treatment of advanced NSCLC and appears to yield an improved therapeutic index versus 3-weekly regimens.
